Cinclus Pharma

Research Cinclus Pharma (CINPHA) on Bullrun: market cap SEK 510.05M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerCINPHA
• ExchangeST
• CountrySweden
• SectorHealthcare
• IndustryDrug Manufacturers - Specialty & Generic
• CurrencySEK
• Market capSEK 510.05M
• Financial periodFY2024
• Net income-SEK 168.03M

Valuation Snapshot

latest market cap is SEK 510.05M.

About Cinclus Pharma

Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori.

Frequently asked questions

What is Cinclus Pharma's market cap?

Cinclus Pharma's market capitalization is SEK 510.05M.

What does Cinclus Pharma do?

Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China.